<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>http://api.elsevier.com/content/abstract/scopus_id/84892364929</prism:url><dc:identifier>SCOPUS_ID:84892364929</dc:identifier><eid>2-s2.0-84892364929</eid><pubmed-id>24365044</pubmed-id><prism:doi>10.1016/j.thromres.2013.10.043</prism:doi><dc:title>Detection of platelet sensitivity to inhibitors of COX-1, P2Y1, and P2Y12 using a whole blood microfluidic flow assay</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><citedby-count>3</citedby-count><prism:publicationName>Thrombosis Research</prism:publicationName><source-id>20648</source-id><prism:issn>00493848</prism:issn><prism:volume>133</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:startingPage>203</prism:startingPage><prism:endingPage>210</prism:endingPage><prism:pageRange>203-210</prism:pageRange><prism:coverDate>2014-02-01</prism:coverDate><dc:creator><author auid="55807517200" seq="1"><ce:initials>R.</ce:initials><ce:indexed-name>Li R.</ce:indexed-name><ce:surname>Li</ce:surname><ce:given-name>Ruizhi</ce:given-name><preferred-name>
<ce:initials>R.</ce:initials>
<ce:indexed-name>Li R.</ce:indexed-name>
<ce:surname>Li</ce:surname>
<ce:given-name>Ruizhi</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/55807517200</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60006297" id="60006297"/></author></dc:creator><dc:description><abstract original="y" xml:lang="eng">
<ce:para>Background Microfluidic devices recreate the hemodynamic conditions of thrombosis. Methods Whole blood inhibited with PPACK was treated ex vivo with inhibitors and perfused over collagen for 300 s (wall shear rate = 200 s <sup>- 1</sup>) using a microfluidic flow assay. Platelet accumulation was measured in the presence of COX-1 inhibitor (aspirin, ASA), P2Y<inf>1</inf> inhibitor (MRS 2179), P2Y<inf>12</inf> inhibitor (2MeSAMP) or combined P2Y <inf>1</inf> and P2Y<inf>12</inf> inhibitors. Results High dose ASA (500 μM), 2MeSAMP (100 μM), MRS 2179 (10 μM), or combined 2MeSAMP and MRS 2179 decreased total platelet accumulation by 27.5%, 75.6%, 77.7%, and 87.9% (p &lt; 0.01), respectively. ASA reduced secondary aggregation rate between 150 and 300 s without effect on primary deposition rate on collagen from 60 to 150 s. In contrast, 2MeSAMP and MRS 2179 acted earlier and reduced primary deposition to collagen between 60 and 105 s and secondary aggregation between 105 and 300 s. R<inf>COX</inf> and R<inf>P2Y</inf> (defined as a ratio of secondary aggregation rate to primary deposition rate) demonstrated 9 of 10 subjects had R <inf>COX</inf> &lt; 1 or R<inf>P2Y</inf> &lt; 1 following ASA or 2MeSAMP addition, while 6 of 10 subjects had R<inf>P2Y</inf> &lt; 1 following MRS 2179 addition. Combined MRS 2179 and 2MeSAMP inhibited primary platelet deposition rate and platelet secondary aggregation beyond that of each individual inhibitor. Receiver-Operator Characteristic area under the curve (AUC) indicated the robustness of R<inf>COX</inf> and R<inf>P2Y</inf> to detect inhibition of secondary platelet aggregation by ASA, 2MeSAMP, and MRS 2179 (AUC of 0.874 0.966, and 0.889, respectively). Conclusions Microfluidic devices can detect platelet sensitivity to antiplatelet agents. The R-value can serve as a self-normalized metric of platelet function for a single blood sample. © 2013 Elsevier Ltd © 2013 Published by Elsevier Ltd.</ce:para>
</abstract></dc:description><link href="http://api.elsevier.com/content/abstract/scopus_id/84892364929" rel="self"/><link href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84892364929&amp;origin=inward" rel="scopus"/><link href="http://api.elsevier.com/content/search/scopus?query=refeid%282-s2.0-84892364929%29" rel="cited-by"/></coredata><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60006297" id="60006297"><affilname>University of Pennsylvania</affilname></affiliation><authors><author auid="55807517200" seq="1"><ce:initials>R.</ce:initials><ce:indexed-name>Li R.</ce:indexed-name><ce:surname>Li</ce:surname><ce:given-name>Ruizhi</ce:given-name><preferred-name>
<ce:initials>R.</ce:initials>
<ce:indexed-name>Li R.</ce:indexed-name>
<ce:surname>Li</ce:surname>
<ce:given-name>Ruizhi</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/55807517200</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60006297" id="60006297"/></author><author auid="7202852214" seq="2"><ce:initials>S.L.</ce:initials><ce:indexed-name>Diamond S.L.</ce:indexed-name><ce:surname>Diamond</ce:surname><ce:given-name>Scott L.</ce:given-name><preferred-name>
<ce:initials>S.L.</ce:initials>
<ce:indexed-name>Diamond S.</ce:indexed-name>
<ce:surname>Diamond</ce:surname>
<ce:given-name>Scott L.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/7202852214</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60006297" id="60006297"/></author></authors></abstracts-retrieval-response>
